SBI PRESS RELEASES
WINDOWS\DESKTOP\bpharma
Public Relations Contact:
 
Alicia Althoff
Marketing Communications Coordinator
alicia@strubix.com

Structural Bioinformatics Inc.
10929 Technology Place
San Diego, CA 92127
Tel: (858) 675-2400 x119
Fax: (858) 618-1041
 
http://www.strubix.com

 
ARQULE SUBSCRIBES TO SBI's PROMAXTM 3-DIMENSIONAL PROTEOMICS DATABASE

 SAN DIEGO, CA - (March 8, 2001) - Privately held Structural Bioinformatics, Inc. (SBI) today announced that that ArQule has subscribed to SBI's ProMaxTM 3-dimensional drug target protein structure database. Under the terms of the agreement, ArQule has access to the database containing multiple families of SBI's highly accurate, computationally derived 3-D protein structures.

"Structure is the key to unlocking the coming post-genomic revolution in human medicine," said Dr. Edward T. Maggio, Chairman, President and Chief Executive Officer of SBI. "ArQule is a leader in development of innovative proprietary technologies for drug discovery, collaborating with a growing number of leading pharmaceutical companies. ArQule's subscription to SBI's ProMaxTM database represents continued validation of the value and utility of large-scale protein structural information. SBI is very pleased to be working with ArQule to assist in furthering their objectives."

Joe Fanelli, Vice President of Marketing & Sales for SBI, further elaborated on the functionality the database provides to its customers. "Among the many uses of the ProMaxTM protein structure database is the integration of SBI's proprietary protein structural content with combinatorial chemical libraries to rapidly and accurately structurally discriminate specific targets of interest from unintended targets. Using this approach, the specificity of drug libraries for specific targets can be substantially enhanced."

About Structural Bioinformatics, Inc.

SBI is a world leader in computational proteomics -- the large-scale generation and use of protein structure and protein structural information. The Company has developed advanced technologies to generate highly refined 3-dimensional structural models of proteins from primary genetic information and commercializes these technologies through its structural database products and through drug discovery collaborations with leading pharmaceutical companies. SBI has offices and research facilities in San Diego, CA; Cambridge, MA; Washington, DC; and Hørsholm, Denmark. More information about SBI can be found on the company's website at: http://www.strubix.com.